Good evening and welcome to Markets Desk, your close of business briefing on the stories moving markets and the world.
The United States and Venezuela have struck an oil agreement, but anyone expecting immediate relief at the pump should temper their expectations. The deal is largely diplomatic in nature, layered with political risk and structural constraints that keep Venezuelan crude from reaching American refiners at any meaningful scale anytime soon. Watch this one carefully over the coming weeks.
Shifting to biotech, Viking Therapeutics has seen its stock shed sixty-six percent from its peak, a brutal drawdown for a name that was briefly a market darling. The company's lead obesity candidate, VK two seven three five, retains genuine dual-formulation promise across injectable and oral delivery, but investors are now demanding clinical proof before they'll re-rate the stock. The next data readout is everything here.
And in the nuclear space, X-Energy has entered public markets with an interesting pitch — using artificial intelligence to compress the timeline on reactor design, a process that has historically taken decades. Whether AI can meaningfully de-risk the capital intensity of nuclear development remains an open question, but the market is clearly willing to assign a premium to the story right now.
That's the tape. Markets Desk, signing off the floor.
